

Therapy of Schizophrenia

Yacoub M. Irshaid, MD, PhD, ABCP

Department of Pharmacology

Therapy of Schizophrenia

- Schizophrenia represents a heterogeneous syndrome of disorganized and bizarre thoughts, delusions, hallucinations, inappropriate affect, and impaired psychosocial functioning.
- Multiple neurotransmitter dysfunctions are involved in schizophrenia.
- The etiology is more likely mediated by multiple subcellular processes that are influenced by different genetic polymorphisms.
- Drugs used in the therapy of schizophrenia are the **antipsychotic drugs**.

Therapy of Schizophrenia

- Antipsychotics are similar regarding the beneficial effect.
- Therefore, adverse effect profiles are important for appropriate selection of an antipsychotic drug for an individual patient.
- Pharmacotherapy guidelines emphasize antipsychotics monotherapies with adequate benefit/risk ratios.
- Antipsychotics have may disturbing and severe adverse effects.
- Combination regimens should only be used in the most treatment-resistant patients.

Therapy of Schizophrenia

- Long-term maintenance antipsychotic treatment is needed for the vast majority of patients in order to prevent relapse.
- Psychosocial rehabilitation programs should be used in combination with antipsychotic treatment to be effective.
- Most deterioration in psychosocial functioning occurs during the first 5 years after the initial psychotic episode, and treatment should be particularly used during this period.

Drug-Induced Psychosis

- 1. Cannabis, Marijuana
 - 2. Cocaine
 - 3. Amphetamines: ecstasy (MDMA), methamphetamine, methylphenidate
 - 4. LSD
 - 5. Phencyclidine and ketamine
 - 6. Alcohol
-
- Patients with schizophrenia who continue to abuse alcohol or drugs usually have a poor response to medications and a poor prognosis.
 - Opioids
 - Drugs for Parkinsonism
 - NSAIDs
 - Digitalis
 - Beta-blockers
 - Corticosteroids
 - Antihistamines
 - Sedatives, benzodiazepines
 - Mushrooms poisoning
 - Others

Medical Causes of Psychosis

- HIV (AIDS)
- Malaria
- Syphilis
- Alzheimer's disease
- Parkinson's disease
- Hypoglycemia
- SLE
- Multiple sclerosis

Therapy of Schizophrenia

Desired Outcome:

1. Avoiding unwanted adverse effects of therapy.
2. Integrating the patient back into the community.
3. Increasing adaptive functioning.
4. Preventing relapse.

TABLE 29–1 Antipsychotic drugs: Relation of chemical structure to potency and toxicities.

Chemical Class	Drug	D ₂ /5-HT _{2A} Ratio ¹	Clinical Potency	Extrapyramidal Toxicity	Sedative Action	Hypotensive Actions
Phenothiazines						
Aliphatic	Chlorpromazine	High	Low	Medium	High	High
Piperazine	Fluphenazine	High	High	High	Low	Very low
Thioxanthene	Thiothixene	Very high	High	Medium	Medium	Medium
Butyrophenone	Haloperidol	Medium	High	Very high	Low	Very low
Dibenzodiazepine	Clozapine	Very low	Medium	Very low	Low	Medium
Benzisoxazole	Risperidone	Very low	High	Low ²	Low	Low
Thienobenzodiazepine	Olanzapine	Low	High	Very low	Medium	Low
Dibenzothiazepine	Quetiapine	Low	Low	Very low	Medium	Low to medium
Dihydroindolone	Ziprasidone	Low	Medium	Very low	Low	Very low
Dihydrocarbostyril	Aripiprazole	Medium	High	Very low	Very low	Low

¹Ratio of affinity for D₂ receptors to affinity for 5-HT_{2A} receptors.²At dosages below 8 mg/d.

Therapy of Schizophrenia

Antipsychotics:

1. **First-Generation Antipsychotics (FGAs):** Chlorpromazine, Haloperidol, Thiothixine, Loxapine.
 - Mechanism: They block dopaminergic neurotransmission mainly. They also have noradrenergic, cholinergic, and histaminergic blocking action.
2. **Second-Generation Antipsychotics (SGAs):** Aripiprazole, Clozapine, Olanzapine, Quetiapine, Risperidone, Ziprasidone.
 - Mechanism: blocking D_2 dopamine receptors as well as $5-HT_{2A}$ serotonin receptor.

Therapy of Schizophrenia

Pharmacologic Therapy:

- Exclude general medical or substance-induced causes of psychosis.
- Use a drug that produce antipsychotic response with few or no acutely occurring extrapyramidal adverse effects (EPS).
- The major advantage of SGAs is their lower risk of neurologic adverse effects, particularly motor effects.
- However, **some SGAs have increased risk of metabolic adverse effects**, such as, **weight gain, hyperlipidemias, and diabetes mellitus.**

Therapy of Schizophrenia

A. Initial Treatment of an Acute Psychotic Episode:

- The goals during the first 7 days of treatment should be reduction of symptoms (agitation, hostility, combativeness, anxiety, tension, and aggression) and normalization of sleep and eating patterns.
- In first-episode psychotic patients, typical dosing ranges are ~ 50% of the doses used in chronically ill individuals, because of increased susceptibility to EPS. (**aripiprazole, risperidone or ziprasidone have the least EPS adverse reactions**).

Therapy of Schizophrenia

- Previously treated patients: use any antipsychotic **except clozapine** and **antipsychotics that were not effective or poorly tolerated** by the patient.
- **clozapine monotherapy** may be attempted in patients:
 - a) who were not responsive with 2 antipsychotic trials,
 - b) who were severely suicidal.

Therapy of Schizophrenia

B. Stabilization Therapy:

- If the patient begins to show adequate response at a particular dose, then the patient should continue at this dose.
- Improvement is usually a slow but steady process over 6 - 12 weeks or longer:
 - a) Increased socialization and improvement in self-care habits and mood take 2-3 weeks to occur.
 - b) Improvement in formal thought disorder can take an additional 6 - 8 weeks to occur.
 - c) Chronically ill patients may need 3-6 months to improve.

Therapy of Schizophrenia

- Before changing medications in a poorly responding patient, the following should be considered:
 1. Confirm the diagnosis of schizophrenia, or exclude a different diagnosis, a long-standing behavioral problem, a substance abuse disorder, or a general medical condition.
 2. Check whether the patient has a treatment-resistant schizophrenia.
- Medications are effective at decreasing the symptoms of schizophrenia (palliative), but they are not curative. Some symptoms may remain.

Therapy of Schizophrenia

C. Maintenance Therapy:

- Maintenance drug therapy prevents relapse.
- After treatment of the first psychotic episode, medication should be continued for 1 - 5 years after remission.
- In chronically ill individuals, continuous or lifetime pharmacotherapy is necessary in the majority of patients to prevent relapse, using the **lowest, effective and tolerable** dose of the antipsychotic.

Therapy of Schizophrenia

- Antipsychotics **should be tapered slowly** over at least 1 - 2 weeks while the second antipsychotic is initiated and the dose titrated up.
- Antipsychotic tapering needs to occur more slowly with **clozapine**.
- Abrupt discontinuation, especially for **clozapine**, can result in **withdrawal symptoms**: Insomnia, nightmares, headaches, GI symptoms (abdominal cramps, stomach pain, nausea, vomiting, and diarrhea), restlessness, increased salivation, and sweating.

Therapy of Schizophrenia

Long-Acting Injectable (LAI) Antipsychotics:

- Used for patients who are unreliable in taking oral medication on a daily basis.
- It may be offered as a treatment option earlier in treatment before patients become non-adherent to therapy.
- Before declaring a patient non-adherent, the cause should be identified.

Therapy of Schizophrenia

- If medication nonadherence is due to adverse effects, an alternative medication with a more favorable adverse effect profile should be considered before a long-acting injectable antipsychotic is given.
- **Paliperidone palmitate** is a long-acting injectable antipsychotic (once-monthly IM injection).
- **Aripiprazole** is available as once monthly injection that requires 2 - 3 weeks of oral antipsychotic overlap.

Therapy of Schizophrenia

- **Olanzapine** can be used as LAI administered every 2 - 4 weeks.
- It may be associated with a post-injection delirium/sedation syndrome in 2% of patients.
- The injection must be administered in a healthcare facility, and the patient must be observed for at least 3 hours after administration and must not drive or operate machinery for that day.

Therapy of Schizophrenia

Management of Treatment-Resistant Schizophrenia:

- “Treatment Resistant” describes a patient who has had **inadequate response from multiple antipsychotic trials**.
- In patients failing ≥ 2 pharmacotherapy trials, reexamine diagnosis, exclude substance abuse, medication non-adherence, and psychosocial stressors.
- Targeted cognitive behavioral therapy or psychosocial augmentation strategies should be considered.

Therapy of Schizophrenia

- **Clozapine** may be effective in the management of treatment-resistant schizophrenia.
- Symptomatic improvement occurs slowly (over 6 months).
- It has been effective in: **patients with severe suicidality**, **aggressive behavior**, or **those who cannot tolerate neurologic adverse effects** of even low doses of other antipsychotics.
- Its use requires **Absolute Neutrophil Count (ANC) monitoring**.

Therapy of Schizophrenia

- Because of the risk of orthostatic hypotension, clozapine is usually titrated more slowly than other antipsychotics, particularly on an outpatient basis.
- **Clozapine dose:** should not exceed 900 mg daily.
- Initial dose: 12.5 mg orally once or twice a day
Titration and Maintenance dose: May increase total daily dose in increments of 25 - 50 mg per day to a target dose of 300 - 450 mg per day (administered in divided doses) by the end of week 2.

Therapy of Schizophrenia

Clozapine Monitoring:

- A therapeutic window of 0.35 - 0.5 mg/L is suggested.
- Plasma levels greater than 0.6 mg/L are related to an increased risk of **convulsions**.
- Levels of around 0.6-0.8 mg/L have been proposed as the upper therapeutic limit.
- There is a clearer link between seizures and plasma levels over 1.0 mg/L and other types of toxicity with levels over 0.75 mg/L.
- For levels >1 mg/L, consider cautious dose reduction and LFT (**Liver Function Test**) measurement.
- The norclozapine level under normal circumstances is expected to be around two thirds of the clozapine level.
- The plasma trough clozapine:norclozapine ratio (**clozapine metabolic ratio**) provides a simple measure of clozapine metabolism in individuals.

Therapy of Schizophrenia

Pharmacokinetics:

- Antipsychotics are highly lipophilic and highly bound to membranes and plasma proteins, and have large volumes of distribution.
- Most antipsychotics are largely metabolized by CYPs.
- For those metabolized by CYP2D6, metabolism is polymorphic as patients may be poor, intermediate, rapid , or ultrarapid metabolizers.

Therapy of Schizophrenia

- That is especially important for dosing and monitoring of antipsychotics.
- Most antipsychotics have long elimination half-lives ≥ 24 hours, with the exception of quetiapine and ziprasidone, which have shorter half-lives (2-10 hours).

Therapy of Schizophrenia

Adverse Effects:

Endocrine System:

1. Hyperprolactinemia due to dopamine blockade in the tuberoinfundibular system. It is associated with gynecomastia, galactorrhea, menstrual irregularities, decreased libido, and sexual dysfunction.
2. Weight gain: it has been associated with antihistaminic effects, antimuscarinic effects, and blockade of 5-HT_{2C} receptors.

Therapy of Schizophrenia

Cardiovascular System:

1. Orthostatic Hypotension (α -adrenergic blockade).
2. Sudden cardiac death.
3. Elevation of serum triglycerides and cholesterol.
4. Sinus tachycardia from anticholinergic effects.
5. Reflex tachycardia from α -adrenergic blockade.
6. Prolongation of QTc, which may be associated with polymorphic ventricular arrhythmias, including torsade de pointes syndrome.
Most common with **thioridazine and ziprasidone**, but can be caused by other antipsychotics.

Therapy of Schizophrenia

Anticholinergic Adverse Effects:

- Dry mouth, constipation, tachycardia, blurred vision, impairment of erection, urinary retention, or **impaired memory**.
- Paralytic ileus and necrotizing enterocolitis can also occur.

Therapy of Schizophrenia

Central Nervous System:

A. Extrapiramidal Symptoms:

- They are movement disorders due to excess dopamine blockade in the nigrostriatal pathway.

1. Dystonia:

- **Prolonged tonic contractions**, usually within 1-4 days of initiating or increasing the dose of an antipsychotic.
- They can be life-threatening, as in the case of pharyngeal-laryngeal dystonias

Therapy of Schizophrenia

- They can contribute to patient nonadherence.
- They include trismus, glossospasm, tongue protrusion, pharyngeal– laryngeal dystonia, blepharospasm, oculogyric crisis (spasmodic movements of the eyeballs into a fixed position, usually upwards), torticollis, and retrocollis.
- The risk of dystonia is greatly reduced with SGAs.
- Dystonia may be treated with Intramuscular or IV anticholinergics (restore balance between acetylcholine and dopamine) or benzodiazepines (central muscle relaxants).

Therapy of Schizophrenia

2. Akathisia:

- It is defined as the inability to sit still, associated with functional motor restlessness (pacing, shifting, shuffling, or tapping feet).
- Akathisia is common with some FGAs, frequently accompanied by **dysphoria**.
- May be associated with **insomnia**, **increased suicidality** and development of tardive dyskinesia.
- **Quetiapine and clozapine** appear to have the lowest risk of producing akathisia.

Therapy of Schizophrenia

- 5-HT₂ receptor antagonist (cyproheptadine, mirtazapine, and trazodone) may be protective against akathisia and may be used for its management.
- Benzodiazepines may be used, but not in the case of substance abuse.
- The β-blockers (propranolol, nadolol, and metoprolol) may be effective.

Therapy of Schizophrenia

3. Pseudoparkinsonism:

- Due to D_2 blockade in the nigrostriatum.
- More common with FGAs.
- The onset is typically 1 - 2 weeks after initiation or a dose increase.
- Can be treated with anticholinergic drugs (**trihexyphenidyl**, **benztropine**, **orphenadrine**), but may produce euphoria (**potential for abuse**).
- Amantadine may be effective.

Therapy of Schizophrenia

- **Rotigotine**, a dopamine agonist, may be effective.
- The risk of pseudoparkinsonism with SGAs is low, but may occur with **risperidone** at relatively large doses.
- **Quetiapine, aripiprazole, and clozapine** are reasonable alternatives in a patient experiencing EPS with other SGAs.

Therapy of Schizophrenia

4. Tardive Dyskinesia (TD):

- It is a syndrome characterized by delayed abnormal involuntary movements buccal–lingual–masticatory, or orofacial.
- The onset is usually insidious, and appears late after initiation.
- The first detectable signs of tardive dyskinesia are mild forward, backward, or lateral movements of the tongue.
- It is associated with higher overall morbidity and mortality.
- More prevalent with FGAs (20 - 50%).

Therapy of Schizophrenia

- Short-term treatment of TD with either **clonazepam** (due to enhanced GABA effects) **or ginkgo biloba** (as antioxidant) may be effective.
- **Clozapine** decreases abnormal involuntary movements.

Therapy of Schizophrenia

B. Sedation:

- **Chlorpromazine, thioridazine, clozapine, olanzapine, and quetiapine** are the most sedating antipsychotics.
- Administration of most or all of the daily dosage at bedtime can decrease daytime sedation.
- Sedation occurs early in treatment and may decrease over time.

Therapy of Schizophrenia

C. Seizures:

- Antipsychotics decrease the seizure threshold.
- Seizures have been reported with most antipsychotics, but the highest risk is with **clozapine or chlorpromazine**.
- Lowest potential for seizures is with **risperidone, thioridazine, haloperidol, pimozide, trifluoperazine, and fluphenazine**.

Therapy of Schizophrenia

D. Neuroleptic Malignant Syndrome (NMS):

- (NMS) occurs in 0.5% - 1% of patients receiving FGAs.
- Less common with SGAs, including clozapine.
- It develops rapidly, over the course of 24 - 72 hours.
- NMS can occur after antipsychotic discontinuation, especially when depot agents are used.
- Possible mechanisms include disruption of the central thermoregulatory process or excess production of heat secondary to skeletal muscle contractions.

Therapy of Schizophrenia

- Signs and symptoms: temperature $> 38^{\circ}\text{C}$, loss of consciousness, autonomic dysfunction (tachycardia, labile blood pressure, diaphoresis, tachypnea, or urinary or fecal incontinence), and muscle rigidity.
- Associated with leukocytosis and increased creatine kinase (CK), AST, ALT, LDH, and myoglobinuria.
- Treatment should begin with antipsychotic discontinuation and supportive care.
- **Bromocriptine, amantadine, dantrolene** (skeletal muscle relaxant) are effective.

Therapy of Schizophrenia

Ophthalmologic Effects:

- Exacerbation of narrow-angle (angle-closure) glaucoma (anticholinergic effect).
- Opaque deposits in the cornea and lens (chlorpromazine).
- Cataract (risperidone and quetiapine).
- Retinitis pigmentosa (thioridazine doses > 800 mg daily), due to melanin deposits and can result in permanent visual impairment or blindness.

Therapy of Schizophrenia

Genitourinary System:

1. Urinary hesitancy and retention secondary to anticholinergic effects (FGAs and clozapine).
2. Urinary incontinence due to α -blockade (clozapine).
3. Sexual dysfunction (dopaminergic blockade, hyperprolactinemia, histaminergic blockade, anticholinergic effects, and α -adrenergic blockade). Manifested by decreased libido, erectile dysfunction, difficulty achieving orgasm, and ejaculatory abnormalities.
4. Priapism (unprovoked sustained and painful erection). May be due to α_1 -adrenergic receptor blockade, leading to intracavernosal blood stasis).

Therapy of Schizophrenia

Hematologic System:

- **Agranulocytosis (clozapine (0.8%), chlorpromazine, and olanzapine).**
- The onset is usually within the first 8 weeks of therapy.
- If the absolute neutrophil count (ANC) is $< 500/\mu\text{L}$, the antipsychotic should be discontinued and the ANC monitored closely until it returns to normal and also monitored closely for the development of infections.

Therapy of Schizophrenia

- The baseline ANC must be at least $1,500/\mu\text{L}$ in order to start clozapine.
- Weekly ANC monitoring for the first 6 months of therapy is required. Then every 2 weeks for the next 6 months.
- After this, monitoring can be decreased to monthly if all ANCs remains greater than $1,500/\mu\text{L}$.
- If at any time the ANC drops to less than $500/\mu\text{L}$, clozapine must be discontinued.

Therapy of Schizophrenia

Skin:

- Contact dermatitis
- Skin reaction with Eosinophilia (ziprasidone).
- Photosensitivity (all, especially chlorpromazine).
- Blue-gray or purplish skin coloration in areas exposed to sunlight (chlorpromazine), concurrent with corneal or lens pigmentation.
- Exposure to sunlight should be limited (blocking sunscreen, hats, protective clothing, and sunglasses).

Therapy of Schizophrenia

Miscellaneous Adverse Effects:

- **Sialorrhea (drooling) in 54% of patients (Clozapine).**
- May be due to antagonistic effect on both α_1 - and α_2 -adrenergic receptors at the salivary glands leading to vasodilation and increased blood flow.
- Anticholinergics such as benztrapine and atropine, and α_2 -agonists such as clonidine have been used to treat clozapine-related sialorrhea.

Therapy of Schizophrenia

Use during pregnancy:

- There is a slightly increased risk of birth defects with FGAs.
- Haloperidol is the best studied of all antipsychotics, and no relationship between its use and teratogenicity has been found.
- Elevated risk of preterm birth in patients taking FGAs.
- Increased risk of cardiovascular defects with FGAs.

Therapy of Schizophrenia

Gestational postnatal and complications:

1. Weight gain (olanzapine and clozapine).
2. Increased risk of gestational diabetes (olanzapine and clozapine).
3. Increased risk of hypertension as well as venous thromboembolism.
4. Risk of neonatal EPS (FGAs), with effects lasting for 3 - 12 months after birth.
5. The FDA issued a safety announcement that the pregnancy risk applies for the entire antipsychotic class, highlighting the potential risk for EPS and withdrawal symptoms in newborns whose mothers were treated with antipsychotics during their third trimester.

Therapy of Schizophrenia

Use During Lactation:

- Antipsychotics appear in breast milk with milk-to-plasma ratios of 0.5:1.
- One week after delivery, clozapine milk concentrations may reach 3X the plasma concentrations.
- Clozapine use during breast-feeding is **NOT** recommended due to the risk of bone marrow suppression.
- Aripiprazole and quetiapine are generally considered safe during breastfeeding.

Therapy of Schizophrenia

- Infants exposed to chlorpromazine through breast milk may become drowsy and lethargic.
- The co-administration of chlorpromazine and haloperidol may result in developmental delays at 12 - 18 months of age.
- The lowest effective dose of antipsychotics should be used in the mother, and the infant carefully monitored for antipsychotic adverse effects such as EPS, sedation, seizures and developmental delays.

Therapy of Schizophrenia

Pharmacodynamic Drug Interactions:

1. Excess sedation when antipsychotics are used with other sedative.
2. Additive antimuscarinic effects with other antimuscarinic drugs.
3. Both combined sedative and anticholinergic effects from multiple medications can result in **impaired cognition**, particularly in the elderly.
4. More orthostatic hypotension when used with other drugs that cause orthostasis.

Therapy of Schizophrenia

5. Metoclopramide lead to more akathisia and other EPS if it is used concomitantly with antipsychotics.
6. Careful monitoring is required when drugs that prolong the QTc interval are coadministered with antipsychotics having the same effect or with diuretics that produce hypokalemia.

Therapy of Schizophrenia

7. SSRIs can interact with antipsychotics:
 - a) 5-HT₂ receptors are present on the presynaptic dopaminergic neuron, and their activation leads to decreased DA release from the presynaptic terminal.
 - b) Increased availability of 5-HT through SSRI effect can, thus, decrease DA release and add to the dopaminolytic effects of antipsychotics.
 - c) SSRIs can precipitate akathisia or EPS when added to a patient stabilized on an antipsychotic.

Therapy of Schizophrenia

Pharmacokinetic Drug Interactions:

- Antipsychotic drugs are metabolized by CYP2D6, CYP3A4 and CYP1A2.
- More than one of these isoenzymes may also metabolize a particular antipsychotic agent.
- Knowledge of common substrates, inducers and inhibitors of CYPs is necessary to predict the kind of interaction, when antipsychotics are co-administered with other drugs.